Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-23-012903
Filing Date
2023-04-14
Accepted
2023-04-14 16:26:19
Documents
7
Period of Report
2023-06-28

Document Format Files

Seq Description Document Type Size
1 PRE 14A trvi_-_pre_14a_-_2023.htm PRE 14A 1163216
2 GRAPHIC img117601486_0.jpg GRAPHIC 55345
3 GRAPHIC img117601486_1.jpg GRAPHIC 20442
4 GRAPHIC img117601486_2.jpg GRAPHIC 55345
5 GRAPHIC img117601486_3.jpg GRAPHIC 20442
6 GRAPHIC img117601486_4.jpg GRAPHIC 144580
7 GRAPHIC img117601486_5.jpg GRAPHIC 96174
  Complete submission text file 0000950170-23-012903.txt   1695958
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38886 | Film No.: 23821497
SIC: 2834 Pharmaceutical Preparations